Overview

Study to Investigate Effects of Antiischemic Drug Therapy in Silent Ischemia

Status:
Completed

Trial end date:
2006-04-01

Target enrollment:
0

Participant gender:
All

Summary

There is a lack of data on the prognostic importance of silent ischemia in totally asymptomatic subjects without history of coronary artery disease (CAD), and, particularly, on a possible benefit of medical therapy in such patients. SWISSI 1 therefore recruits totally asymptomatic subjects older than 40 years of age without any history of CAD but one cardiovascular risk factor with documented silent ischemia. Participants are randomized to open antianginal drug therapy and risk factor control versus only risk factor management and followed up for ≥ 10 years.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Luzerner Kantonsspital

Treatments:

Amlodipine
Aspirin
Bisoprolol
Molsidomine

Criteria

Inclusion Criteria:

- Documented silent myocardial ischemia type I

- At least one cardiovascular risk factor

Exclusion Criteria:

- History of cardiovascular disease